CGRP Inhibitors: Transforming Migraine Management and Beyond
- MigraineMind
- Nov 27, 2025
- 1 min read
Research Summary
The therapeutic targeting of calcitonin gene-related peptide (CGRP) has revolutionized migraine treatment, establishing it as a manageable neurological disorder. Published in the Annual Review of Medicine, this review highlights the approval of eight monoclonal antibodies and small-molecule receptor antagonists by the FDA for both acute and preventive migraine care. These CGRP inhibitors have demonstrated remarkable safety in real-world settings, though some adverse effects are emerging. Additionally, the study speculates on the potential use of CGRP inhibitors for other disorders and envisions future combinatorial and neuropeptide-based treatments, inspired by the success story of CGRP in migraine therapy.
Study Details
👥 Research Team: Russo AF, Kaiser EA
📚 Published In: Annu Rev Med
📅 Publication Date: 2025 Nov 26
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.